Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Mult

Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study is a phase 2, interventional study registered as NCT06234007 by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, with a registry enrolment figure of 45 participants, started 2023-12-01 and due to reach its primary completion in 2024-12-31. Interventions recorded: Fruquintinib, Adebrelimab, Oxaliplatin, Capecitabine. Conditions listed: Locally Advanced Rectal Cancer. Primary outcome: pathology complete response(pCR). Colorectal eligibility wording from the registry: "Locally advanced rectal adenocarcinoma confirmed by histopathology;". Sites: China. No results are recorded here; the registry entry is the source.